Scientific publications

Outcome of allogeneic haematopoietic cell transplantation in eosinophilic disorders: A retrospective study by the chronic malignancies working party of the EBMT

Apr 28, 2022 | Magazine: British Journal of Haematology

Donal P McLornan  1 , Luuk Gras  2 , Ivonne Martin  2 , Tiarlan Sirait  3 , Thomas Schroeder  4 , Igor Wolfgang Blau  5 , Jürgen Kuball  6 , Jenny Byrne  7 , Matthew Collin  8 , Michael Stadler  9 , Déborah Desmier  10 , Urpu Salmenniemi  11 , Pavel Jindra  12 , Natalia Mikhailova  13 , Stig Lenhoff  14 , Jose Rifón  15 , Marie Robin  16 , Montserrat Rovira  17 , Hendrik Veelken  18 , Alicja Sadowska-Klasa  19 , Marco Zecca  20 , Patrick J Hayden  21 , Tomasz Czerw  22 , Juan Carlos Hernández-Boluda  23 , Ibrahim Yakoub-Agha  24

Hypereosinophilic syndrome (HES) and chronic eosinophilic leukaemia (CEL), not otherwise specified (NOS) are rare haematological disorders.1 Allogeneic haematopoietic cell transplantation (allo-HCT) has been reported in single case reports or small case series only for both refractory HES or CEL, NOS and outcomes remain ill-defined.1-3 HES normally demonstrates a male predominance, likely underrecognized, with a variable clinical course.

Fulminant cases, however, are frequently associated with significant morbidity and indeed mortality. Even less common, CEL, NOS is an extremely rare myeloproliferative neoplasm (MPN), frequently demonstrating an aggressive clinical course with significant rates of acute transformation.

We hereby report outcomes from a retrospective, European Group for Blood and Marrow Transplantation (EBMT)-registry-based study of 77 adult patients with a confirmed diagnosis of either HES or CEL, NOS who underwent allo-HCT, representing the largest cohort reported to date.

CITATION  Br J Haematol. 2022 Jul;198(1):209-213.
doi: 10.1111/bjh.18219. Epub 2022 Apr 28

Our authors

Navarre headquarters
Madrid headquarters